Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
出版信息
Clin Lung Cancer. 2004 May;5(6):331-2. doi: 10.1016/s1525-7304(11)70182-6.
Abstract
摘要
相似文献
1
Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.表皮生长因子受体酪氨酸激酶的突变可能预测非小细胞肺癌对吉非替尼的反应。
Clin Lung Cancer. 2004 May;5(6):331-2. doi: 10.1016/s1525-7304(11)70182-6.
2
Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.吉非替尼在非小细胞肺癌中的临床开发及肺癌易瑞沙生存评估试验
Clin Lung Cancer. 2005 Jan;6(4):214-6. doi: 10.1016/s1525-7304(11)70473-9.
3
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。
N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
4
Role of tyrosine kinase inhibitors in lung cancer.酪氨酸激酶抑制剂在肺癌中的作用。
Anticancer Agents Med Chem. 2009 Jun;9(5):569-75. doi: 10.2174/187152009788451879.
5
ERBB2 kinase mutations in lung-cancer tumours.肺癌肿瘤中的ERBB2激酶突变。
Lancet Oncol. 2004 Nov;5(11):647. doi: 10.1016/s1470-2045(04)01626-2.
6
Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.表皮生长因子受体抑制剂的预测因素——靶心命中箭头。
Cancer Cell. 2004 May;5(5):411-5. doi: 10.1016/s1535-6108(04)00122-9.
7
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.靶向治疗：酪氨酸激酶抑制剂——非小细胞肺癌治疗的新标准。
Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168.
8
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.肺癌中的表皮生长因子受体（EGFR）突变：与吉非替尼治疗临床反应的相关性
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
9
Clairvoyance or reliable prediction of the future?透视未来还是对未来的可靠预测？
Ann Oncol. 2007 Mar;18(3):407-8. doi: 10.1093/annonc/mdl503.
10
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].[吉非替尼（易瑞沙）对肺腺癌的肿瘤反应：迈向治疗靶点的分子基础]
Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. doi: 10.1016/s0761-8425(04)71466-7.
Zotero 插件